Search

Displaying results 1 - 10 of 29 in total
DrugBest match

Pembrolizumab

go.drugbank.com/drugs/DB09037
ApprovedInvestigational

Pembrolizumab is a highly selective IgG4-kappa humanized monoclonal antibody against PD-1 receptors. It was generated by grafting the variable sequences of a very high-affinity mouse antihuman PD-1 antibody onto a human IgG4-kappa isotype containing a stabilizing S228P Fc mutation. It contains 32 cysteine residues a...

  1. Drug

    Berahyaluronidase alfa

    go.drugbank.com/drugs/DB22790
    ApprovedInvestigational

    It is used in a fixed-dose combination with [pembrolizumab] for subcutaneous injection.

  2. Drug

    Sacituzumab govitecan

    go.drugbank.com/drugs/DB12893
    ApprovedInvestigational

    [L64779] The European Commission added the first-line monotherapy indication on 22 June 2026 and the first-line combination with pembrolizumab on 21 August 2026.[L64778] … L47606, L47601] The FDA approved first-line TNBC indications on June 24, 2026, as a single agent for patients who are not candidates for PD-1 or PD-L1 inhibitor-based therapy and in combination with pembrolizumab

  3. Drug

    Belzutifan

    go.drugbank.com/drugs/DB15463
    ApprovedInvestigational

    [L64571] Its indications were later extended to ccRCC, as monotherapy and in combination with pembrolizumab, and to PPGL.

  4. Drug

    Lenvatinib

    go.drugbank.com/drugs/DB09078
    ApprovedInvestigational

    Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that ...

  5. Drug

    Vibostolimab

    go.drugbank.com/drugs/DB16420
    Investigational

    Vibostolimab is under investigation in clinical trial NCT04303169 (Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With

  6. Drug

    Enfortumab vedotin

    go.drugbank.com/drugs/DB13007
    ApprovedInvestigational

    Enfortumab vedotin is an antibody-drug conjugate used in the treatment of patients with advanced, treatment-resistant urothelial cancers. It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-di...

  7. Drug

    Quaratusugene ozeplasmid

    go.drugbank.com/drugs/DB19231
    Investigational

    Quaratusugene ozeplasmid is under investigation in clinical trial NCT05062980 (Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-small Lung Cancer).

  8. Drug

    Atamparib

    go.drugbank.com/drugs/DB19028
    Investigational

    Atamparib is under investigation in clinical trial NCT05127590 (RBN-2397 in Combination With Pembrolizumab in Patients With SCCL).

  9. Drug

    Vactosertib

    go.drugbank.com/drugs/DB15310
    Investigational

    Vactosertib is under investigation in clinical trial NCT03724851 (Vactosertib in Combination With Pembrolizumab in Metastatic Colorectal or Gastric Cancer).